Gritgen Advances Hemophilia A Gene Therapy; Completes Manufacturing Plant

Suzhou Gritgen Therapeutics has completed validation of its commercial gene therapy GMP facility and officially opened the plant, which is located in Suzhou Industrial Park. Initially, the company will use the facility to produce Phase III clinical and commercial supplies for its lead candidate, a gene therapy for hemophilia A. Gritgen develops adeno associated virus (AAV) gene therapies, with its next-gen AAV capsid platform and efficient promotors and enhancers. The GMP facility is built to comply with global cGMP standards, including the NMPA, the FDA and the EMA.  More details....